注册 | 登录
所有产品
  • 所有产品
  • 一抗
  • 裂解液
>   首页   >   产品   >   一抗   >   癌症   >   VEGFR3 Antibody   

VEGFR3 Antibody

Mouse Monoclonal Antibody (Mab)

     
标注"皇冠"的产品,是满足高质量标准的产品。
了解更多...
  • 1 - VEGFR3 Antibody AW5293
    Western blot analysis of lysates from A549,T47D cell line (from left to right), using VEGFR3 Antibody(Cat. #AW5293). AW5293 was diluted at 1:1000 at each lane. A goat anti-mouse IgG H&L(HRP) at 1:10000 dilution was used as the secondary antibody.
  • 4 - VEGFR3 Antibody AW5293
    Flow cytometric analysis of HUVEC cells using VEGFR3(green, Cat#AW5293) compared to an isotype control of mouse IgG2a(blue). AW5293was diluted at 1:25 dilution. An Alexa Fluor® 488 goat anti-mouse lgG at 1:400 dilution was used as the secondary antibody.
  • 14 - VEGFR3 Antibody AW5293
    Immunohistochemical analysis of paraffin-embedded H. testis section using VEGFR3(Cat#). was diluted at 1:25 dilution. A peroxidase-conjugated goat anti-mouse IgG at 1:400 dilution was used as the secondary antibody, followed by DAB staining.
  • 14 - VEGFR3 Antibody AW5293
    Immunohistochemical analysis of paraffin-embedded H. kidney section using VEGFR3(Cat#). was diluted at 1:25 dilution. A peroxidase-conjugated goat anti-mouse IgG at 1:400 dilution was used as the secondary antibody, followed by DAB staining.
  • 14 - VEGFR3 Antibody AW5293
    Immunohistochemical analysis of paraffin-embedded R. kidney section using VEGFR3(Cat#NA). NA was diluted at 1:25 dilution. A peroxidase-conjugated goat anti-mouse IgG at 1:400 dilution was used as the secondary antibody, followed by DAB staining.
  • 产品详情
  • 实验流程
  • 背景知识
Product Information
Application
  • Applications Legend:
  • E=ELISA
  • WB=Western Blotting
  • IHC=Immunohistochemistry
  • IHC-P=Immunohistochemistry (Paraffin)
  • IP=Immunoprecipitation
  • IF=Immunofluorescence
  • IC=Immunochemistry
  • ICC=Immunocytochemistry
  • FC=Flow Cytometry
  • DB=Dot Blot
IHC-P, FC, WB
Primary Accession P35916
Reactivity Human
Host Mouse
Clonality Monoclonal
Calculated MW H=153 KDa
Isotype IgG2a
Antigen Source HUMAN
Additional Information
Gene ID 2324
Other Names FLT4;VEGFR3; Vascular endothelial growth factor receptor 3; Vascular endothelial growth factor receptor 3; Fms-like tyrosine kinase 4; Vascular endothelial growth factor receptor 3; Tyrosine-protein kinase receptor FLT4
Dilution WB~~1:1000
FC~~1:25
IHC-P~~1:25
Target/Specificity Purified His-tagged VEGFR3 protein was used to produced this monoclonal antibody.
Format Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, followed by dialysis against PBS.
StorageMaintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
PrecautionsVEGFR3 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.
Protein Information
Name FLT4
Synonyms VEGFR3
Function Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced production of VEGFC, and to a lesser degree VEGFA, thereby creating a positive feedback loop that enhances FLT4 signaling. Modulates KDR signaling by forming heterodimers. The secreted isoform 3 may function as a decoy receptor for VEGFC and/or VEGFD and play an important role as a negative regulator of VEGFC-mediated lymphangiogenesis and angiogenesis. Binding of vascular growth factors to isoform 1 or isoform 2 leads to the activation of several signaling cascades; isoform 2 seems to be less efficient in signal transduction, because it has a truncated C-terminus and therefore lacks several phosphorylation sites. Mediates activation of the MAPK1/ERK2, MAPK3/ERK1 signaling pathway, of MAPK8 and the JUN signaling pathway, and of the AKT1 signaling pathway. Phosphorylates SHC1. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3- kinase. Promotes phosphorylation of MAPK8 at 'Thr-183' and 'Tyr- 185', and of AKT1 at 'Ser-473'.
Cellular Location Cell membrane; Single-pass type I membrane protein. Cytoplasm. Nucleus. Note=Ligand-mediated autophosphorylation leads to rapid internalization Isoform 2: Cell membrane; Single-pass type I membrane protein
Tissue Location Detected in endothelial cells (at protein level). Widely expressed. Detected in fetal spleen, lung and brain. Detected in adult liver, muscle, thymus, placenta, lung, testis, ovary, prostate, heart, and kidney
Research Areas

BACKGROUND

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced production of VEGFC, and to a lesser degree VEGFA, thereby creating a positive feedback loop that enhances FLT4 signaling. Modulates KDR signaling by forming heterodimers. The secreted isoform 3 may function as a decoy receptor for VEGFC and/or VEGFD and play an important role as a negative regulator of VEGFC-mediated lymphangiogenesis and angiogenesis. Binding of vascular growth factors to isoform 1 or isoform 2 leads to the activation of several signaling cascades; isoform 2 seems to be less efficient in signal transduction, because it has a truncated C-terminus and therefore lacks several phosphorylation sites. Mediates activation of the MAPK1/ERK2, MAPK3/ERK1 signaling pathway, of MAPK8 and the JUN signaling pathway, and of the AKT1 signaling pathway. Phosphorylates SHC1. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Promotes phosphorylation of MAPK8 at 'Thr-183' and 'Tyr-185', and of AKT1 at 'Ser-473'.

REFERENCES

Irrthum A., et al. Am. J. Hum. Genet. 67:295-301(2000).
Pajusola K., et al. Cancer Res. 52:5738-5743(1992).
Pajusola K., et al. Cancer Res. 53:3845-3845(1993).
Galland F., et al. Genomics 13:475-478(1992).
Galland F., et al. Oncogene 8:1233-1240(1993).

FeedBack

终于等到您。感谢您使用ABGENT(百奇生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。

如有疑问,联系:0512-69369083 tech.abgent@wuxiapptec.com.


我要评价